You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Logan, Utah-based company's ELISA-based test is designed to detect immunoglobulin G against SARS-CoV-2 in human serum and plasma.
The order is the first from a European government following CE-IVD mark in September. The firm expects to ship 1.2 million of the assays by mid-November.
Quotient recorded a $7.5 million milestone payment in the quarter from Ortho Clinical Diagnostics as part of the companies' restructured distributor arrangement.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 firms' share prices decreased.
Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.
The company is developing a 10-minute, lab-based antigen test as well as a quantitative antibody test that will make use of its sample prep tech.
The firm reported $57.8 million in revenues for its Lyra SARS-CoV-2 molecular diagnostic assays in the quarter.
Thermo Fisher's transplant diagnostics products include antibody detection assays, post-transplant monitoring solutions, HLA typing products, and lab instrumentation.
The ratio of IL-6 to IL-10 biomarkers might give clinicians insight into how severe the inflammatory response to SARS-CoV-2 could be in certain patients.
Kantaro said that authorized clinical testing laboratories in Europe can use its enzyme-linked immunoassays, which detect IgG antibodies to two coronavirus antigens.
The reissued EUA expands the types of samples that may be used with the Broad Institute's PCR-based SARS-CoV-2 test, which was first authorized in July.
Ortho said its antigen test offers 98.9 percent concordance to real-time PCR tests, making it a viable alternative for mass-scale testing during the pandemic.
The test can be used with the Liaison XL, Liaison XS, and Liaison analyzers. More than 8,000 such systems are installed in laboratories worldwide.
Among its recommendations, the FDA said antigen tests for the coronavirus should have a minimum sensitivity of 80 percent for all sample types submitted.
The firm said that its antibody tests detect the presence or absence COVID-19 antibodies and measure their levels.
FIND said the funds were awarded as part of the Access to COVID-19 (ACT) Accelerator Diagnostics Pillar to accelerate testing to help mitigate the pandemic.
The firm saw 120 percent growth in the BioFire FilmArray product line driven by strong demand for a respiratory panel which can detect SARS-CoV-2.
The third quarter continued Abbott's streak of offsetting base business declines with COVID-19 testing, with 38 percent growth in the diagnostics business.
The collaboration will involve the evaluation of serological tests to detect the durability of patients' immune response to COVID-19.
The company said it could produce 3 million antigen tests before the end of this year and between 15 million and 20 million tests per month starting next year.